Bladder Cancer Clinical Trial
Official title:
Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer
Verified date | September 2012 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating
patients with or metastatic urothelial cancer or bladder cancer that has relapsed or not
responded to treatment.
Status | Completed |
Enrollment | 41 |
Est. completion date | August 2012 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed diagnosis of transitional cell tumors of the bladder or the urothelium - Metastatic disease - Relapsed or refractory disease - Measurable disease, defined as = 1 unidimensionally measurable lesion = 2 cm by conventional techniques or = 1 cm by spiral CT scan - Must have failed = 1 cisplatin-based conventional chemotherapy regimen for metastatic disease (neoadjuvant/adjuvant therapy excluded) - No history or clinical evidence of CNS metastases or leptomeningeal carcinomatosis, except for individuals who were previously treated for CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for the past 6 months PATIENT CHARACTERISTICS: - ECOG performance status 0-1 - Life expectancy = 12 weeks - Hemoglobin = 9.0 g/dL - Absolute neutrophil count = 1,000/µL - Platelet count = 75,000/µL - Total bilirubin = 1.5 x upper limit of normal (ULN) - ALT and AST = 2.5 x ULN (= 5 x ULN for patients with liver involvement) - Alkaline phosphatase = 4 x ULN - Serum creatinine = 1.5 mg/dL - PT-INR/PTT < 1.5 x ULN - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception during and for 3 months after completion of study therapy - Able to swallow oral medication - None of the following cardiovascular conditions within the past 6 months: - Cardiac angioplasty or stenting - Myocardial infarction - Unstable angina - Symptomatic peripheral vascular disease - NYHA class III or IV congestive heart failure - Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted) - Uncontrolled hypertension - No history of HIV infection or active chronic hepatitis B or C - No active clinically serious infections > grade 2 NCI-CTC version 4.0 - No seizure disorder requiring medication (e.g., steroids or anti-epileptics) - No history of any of the following conditions within the past 6 months: - Cerebrovascular accident - Pulmonary embolism - Untreated deep venous thrombosis - No evidence or history of bleeding diathesis - No known endobronchial lesions or involvement of large pulmonary vessels by tumor - No hemoptysis within the past 6 weeks - No gastrointestinal abnormalities that may increase the risk of GI bleeding or affect the absorption of investigational study drug - No other cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, or any cancer curatively treated > 5 years prior to study entry - No substance abuse, medical, psychological, or social conditions that may interfere with the study participation or evaluation of the study results - No concurrent unstable condition that could jeopardize patient safety and their compliance in the study - No non-healing wound, fracture, or ulcer within the past 28 days - No major trauma within the past 28 days - No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib hydrochloride PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Recovered from all prior therapy - At least 14 days since prior radiotherapy, except palliative radiotherapy - At least 14 days since tumor embolization - At least 14 days or 5 half-lives (whichever is longer) of a drug since prior chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy - At least 3 weeks since prior biologic response modifiers (e.g., G-CSF) - G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity (e.g., febrile neutropenia) when clinically indicated or at the discretion of the investigator, however they may not be used to avoid a required dose reduction - Chronic erythropoietin allowed provided no dose adjustment is undertaken within 2 months prior to the study or during the study - No prior pazopanib hydrochloride - No coronary artery by-pass graft surgery within the past 6 months - No major surgery within the past 28 days - Concurrent coumadin or heparin for therapeutic anticoagulation allowed provided that no prior evidence of underlying abnormality in PT-INR/PTT parameters exist - Not concurrently undergoing renal dialysis |
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Istituto Nazionale dei Tumori | Milan |
Lead Sponsor | Collaborator |
---|---|
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Italy,
Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R. Pazopanib in advanced and platinum-resistant urothelia — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate (complete and partial response) according to RECIST 1.1 criteria | No | ||
Secondary | Safety and tolerability, in terms of incidence, nature, and severity of treatment-related adverse events according to CTCAE v4.0 | Yes | ||
Secondary | Progression-free survival | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |